2-heptylpyrazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-heptylpyrazine
• 英文别名: Heptylpyrazine
• 化学式: C₁₁H₁₈N₂
• 分子量: 178.277
• InChiKey: CHTGRXRECURHQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  吡嗪 、 辛酸 在 lead(IV) acetate 、 2-氯苯甲酸 作用下， 反应 4.0h， 以80%的产率得到2-heptylpyrazine
  参考文献：
  名称：

  RCOOH-Pb(OAc)4体系无溶剂烷基化N-杂芳族化合物

  摘要：

  Pb(OAc)4 对羧酸的无溶剂脱羧产生烷基自由基，烷基化 4-甲基吡啶、喹啉和用 2-氯苯甲酸质子化的 4-甲基喹啉。吡嗪烷基化需要机械活化。

  DOI：

  10.1007/s11172-005-0347-8

文献信息

• Heterocyclic compounds as PI3K-y inhibitors
  申请人：Incyte Corporation

  公开号：US11091491B2

  公开（公告）日：2021-08-17

  This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

  本申请涉及式 (I) 化合物： 或其药学上可接受的盐或立体异构体，它们是 PI3K-γ 的抑制剂，可用于治疗自身免疫性疾病、癌症、心血管疾病和神经退行性疾病等疾病。
• PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
  申请人：Incyte Corporation

  公开号：US20170246157A1

  公开（公告）日：2017-08-31

  The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
• HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
  申请人：Incyte Corporation

  公开号：US20200031837A1

  公开（公告）日：2020-01-30

  This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
• TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS
  申请人：ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD.

  公开号：US20210332055A1

  公开（公告）日：2021-10-28

  The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.
• US9999619B2
  申请人：——

  公开号：US9999619B2

  公开（公告）日：2018-06-19